Peripheral neuropathy with nucleoside antiretrovirals. Risk factors, incidence and management

Drug Safety

Volumn 19, Issue 6, 1998, Pages 481-494

  Moyle, Graeme J ^a   Sadler, Martin ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALCOHOL; AMITRIPTYLINE; AMPHOTERICIN B; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CIDOFOVIR; CORTICOSTEROID; DAPSONE; DIDANOSINE; ETHIONAMIDE; HYDROXOCOBALAMIN; ISONIAZID; LAMIVUDINE; LEVACECARNINE; METRONIDAZOLE; NUCLEOSIDE ANALOG; PHENYTOIN; PROTEINASE INHIBITOR; RECOMBINANT NERVE GROWTH FACTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VINBLASTINE; VINCRISTINE; ZALCITABINE; ZIDOVUDINE;

ALCOHOL CONSUMPTION; CLINICAL TRIAL; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEUKOCYTE COUNT; ORAL DRUG ADMINISTRATION; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

EID: 0032412213     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819060-00005     Document Type: Review

References (67)

1. DELTA Coordinating Committee. DELTA: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 278-9
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335 (15): 1081-90
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
4. BHIVA Guidelines Co-ordination Committee. British HIV guidelines for antiretroviral treatment of HIV seropositive Individuals. Lancet 1997; 349: 1086-92
5. Carpenter CJC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277: 1962-9
6. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38: 794-6
7. So YT, Holtzman DM, Abrams DI, et al. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988; 45: 945-8
8. Leger JM, Bouche P, Bolgert F, et al. The spectrum of polyneuropathies in patients infected with HIV. J Neurol Neurosurg Psychiatry 1989; 52: 1369-74
9. Snider WD, Simpson DM, Nielsen S, et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 14: 403-18
10. Bacellar H, et al. Temporal trends in incidence of neurologic disease in AIDS [abstract]. 1st National Conference on Human Retroviruses and Related Infections: 1993 Dec; Washington
11. Fuller GN. Cytomegalovirus and the peripheral nervous system in AIDS. J Acquir Immune Defic Syndr 1992; 5 Suppl.: S33-6
12. Tyor WR, Wesselingh SL, Griffin JW, et al. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 379-88
13. Fuller GN, Jacobs JM, Guiloff RJ. Axonal atrophy in the painful peripheral neuropathy in AIDS. Acta Neuropathol 1990; 81: 198-203
14. Fuller GN, Jacobs JM, Guiloff RJ. Subclinical peripheral nerve involvement in AIDS: an electrophysiological and pathological study. J Neurol Neurosurg Psychiatry 1991; 54: 318-24
15. de la Monte SM, Gabuzda DH, Ho DD, et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988; 23: 485-92
16. Bremer J. The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 1990; 28: 297-301
17. Tyor WR, Glass JD, Griffin JW. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol 1992; 31: 349-60
18. Wesselingh SL, Power C, Fox R, et al. Cytokine mRNA expression in HIV-associated neurological disease. Neurology 1993; 43 Suppl. 2: A291
19. Griffin JW, Wesselingh S, Oaklander AL, et al. mRNA fingerprinting of cytokines and growth factors: a new means of characterizing nerve biopsies. Neurology 1993; 43 Suppl. 2: A232
20. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 153-61
21. Garcia G, Smith CI, Weissherg JI, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B: a randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1987; 107: 278-85
22. Pike IM, Nicaise C. The didanosine expanded access program: safety analysis. Clin Infect Dis 1993; 16 Suppl. 1: S63-8
23. Berger AR, Arezzo JC. Schaumburg HH, et al. 2′, 3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993; 43: 358-62
24. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine. Lancet 1988; 1: 76-81
25. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex, results of a phase I trial. N Engl J Med 1990; 322: 1333-40
26. Browne MJ, Mayer KH, Chafee SB, et al. 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993; 167: 21-9
27. Chen C-H, Vazquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-8
28. Keilbaugh SA, Prusoff WH, Simpson VMV. The PC12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV dideoxynucleoside analogs. Biochem Pharmacol 1991; 42 (1): R5-R8
29. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417-22
30. Colucci WJ, Gandour RD. Carnitine acetyltransferase: a review of its biology, enzymology and bioorganic chemistry. Bioorg Chem 1988; 16: 307-34
31. Forloni G, Angeretti N, Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. J Neurosci Res 1994; 37: 92-6
32. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41: 1726-32
33. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992; 49: 1137-41
34. Angelucci L, Ramacci MT, Taglialatela G, et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neurosci Res 1988; 20: 491-6
35. LeLacheur SF, Simon GL. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991; 4: 538-9
36. Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995; 345: 460-1
37. Fuller GN, Jacobs JM, Guiloff RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. J Neurol Neurosurg Psychiatry 1993; 56: 372-81
38. Moyle G, Nelson M, Gazzard B. Quantitative changes in peripheral nerve function in patients receiving didanosine [abstract PO-B26-1995]. IXth International Conference on AIDS: 1993 7-11 Jun; Berlin, 468
39. Berlit P. Klinische Neurologie. VCH: Weinheim. 1992
40. Fichtenhaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 169-74
41. Data on file. F. Hoffman La-Roche
42. Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I/II study. Ann Intern Med 1989; 110: 189-94
43. Meng T-C, Fischl MA, Boota AM. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992; 116: 13-20
44. Skowron G, Bozzette SA, Lim L, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993; 118: 321-30
45. Kieburtz KD, Seidlin M, Lambert JS, et al. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr 1992; 5: 60-4
46. Powderly WG, Klebert MK, Clifford DB. Ototoxicity associated with dideoxycytidine. Lancet 1990; 335: 1106
47. Martinez OP, French MAH. Acoustic neuropathy associated with zalcilabine-induced peripheral neuropathy. AIDS 1993; 7: 901-2
48. 3. Antiviral Ther 1996; 1: 180-8
49. Moyle G, Goll A, Snape S, et al. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advances AIDS-related complex in the European Expanded Access Programme. Int J Antimicrob Agents 1996; 7: 41-8
50. Moyle GJ, Nelson MR, Hawkins D, et al. The use and toxicity of didanosine in HIV antibody positive individuals intolerant to zidovudine (AZT). Q J Med 1993; 86: 155-63
51. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657-62
52. 3: a double-blind controlled trial. Antiviral Ther 1997; 2: 229-36
53. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-inlected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-106
54. Haubrich Laerari J, Follansbee SE, et al. Improved survival and reduced disease progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33-42
55. Stellbrink H-J, the Invirase International Phase III trial (SV-14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients [abstract 212]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection: 1997 Oct 11-15, Hamburg: 21
56. Gazzard BG, Moyle GJ. The role of didanosine in the management of HIV-1 infection. Antiviral Ther 1997; 2: 135-47
57. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-didcoxyinosine (didanosine) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990; 322: 1330-40
58. Connolly KJ, Allan JD, Fitch H, et al. Phase 1 study of 2′,3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and haematological intolerance to zidovudine. Am J Med 1991; 91: 471-8
59. Alpha International Coordinating committee. The Alpha trial: European/Australian randomised doubled-blind trial of two-doses of didanosine in zidovudine intolerant patients with symptomatic HIV disease. AIDS 1996; 10: 867-80
60. Kahn JO, Lapakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-7
61. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171 Suppl.2: S113-S117
62. Peterson EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with the human immunodeficiency virus. J Infect Dis 1995; 171 Suppl. 2: S131-S139
63. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients: a randomized, double-blind, controlled trial. Ann Intern Med 1997; 126; 355-63
64. Gottlieb M, Peterson D, Adler M. Comparison of safety and efficacy of 2 doses of stavudine (Zerit. stavudine) in a large simple trial in the US parallel track program [abstract no. 1171. 35th ICAAC: 1995 Sept 17-20, San Francisco, 235
65. Pollard RB, Peterson D, Hardy D, et al. Randomised double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals. Antiviral Ther 1997; 2 Suppl. 3: 89-93
66. Rossero R, Nokta M, Andron L, et al. Combination therapy with stavudine, didanosine and hydroxyurea in nucleoside experienced HIV-1-infected individuals: a preliminary report. Antiviral Ther 1997; 2 Suppl. 3: 119-23
67. Onofrj M, Fulgente T, Melchionda D, et al. L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Int J Clin Pharmacol Res 1995; 15: 9-15